About the Authors
- Max Lataillade
-
Affiliations Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America, Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, Connecticut, United States of America
- Jennifer Chiarella
-
Affiliation Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, Connecticut, United States of America
- Rong Yang
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Steven Schnittman
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Victoria Wirtz
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Jonathan Uy
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Daniel Seekins
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Mark Krystal
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Marco Mancini
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Donnie McGrath
-
Affiliation Global Development and Medical Affairs, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America
- Birgitte Simen
-
Affiliation 454 Life Sciences, a Roche company, Branford, Connecticut, United States of America
- Michael Egholm
-
Affiliation 454 Life Sciences, a Roche company, Branford, Connecticut, United States of America
- Michael Kozal
-
* E-mail: Michael.kozal@yale.edu
Affiliation Yale University School of Medicine and Veterans Affairs Connecticut Healthcare System, New Haven, Connecticut, United States of America
Competing Interests
MJK is the local primary investigator on HIV therapy studies sponsored by Merck, Pfizer, Gilead, Abbott and Bristol-Myers Squibb. MJK receives laboratory research support from Virco and Bristol-Myers Squibb. MJK receives royalties from a patent owned by Stanford University for some HIV diagnostic tests. BS and ME are employees of 454 Life Sciences/Roche. ML, RY, SS, VW, JU, DS, MK, MM, and DM are employees of Bristol-Myers Squibb. The funding of this study by Bristol Myers Squibb does not alter adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: ML M. Kozal. Performed the experiments: JC BS M. Kozal. Analyzed the data: ML JC RY SS VW BS M. Kozal. Contributed reagents/materials/analysis tools: SS JU DS MK MM DM BS ME MK. Wrote the paper: ML RY SS VW JU DS MK MM DM MK.